TY - JOUR T1 - Characterization of the Diffusion Signal of Breast Tissues using Multi-exponential Models JF - medRxiv DO - 10.1101/2020.04.27.20082271 SP - 2020.04.27.20082271 AU - Ana E. Rodríguez-Soto AU - Maren M. Sjaastad Andreassen AU - Christopher C. Conlin AU - Helen H. Park AU - Grace S. Ahn AU - Hauke Bartsch AU - Joshua Kuperman AU - Igor Vidić AU - Haydee Ojeda-Fournier AU - Anne M. Wallace AU - Michael Hahn AU - Tyler M. Seibert AU - Neil Peter Jerome AU - Agnes Østlie AU - Tone Frost Bathen AU - Pål Erik Goa AU - Rebecca Rakow-Penner AU - Anders M. Dale Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082271.abstract N2 - Background Diffusion-weighted magnetic resonance imaging (DW-MRI) has demonstrated potential as an exogenous contrast-free diagnostic tool for breast cancer screening. Advanced non-Gaussian models of the DW-MRI signal provide insight into the tissue microstructure. Restriction spectrum imaging (RSI) is a mathematical framework that improves tumor conspicuity by decomposing the DW-MRI signal into separate diffusion components. The number of diffusion components and corresponding apparent diffusion coefficients (ADCs) optimal for RSI are organ-specific and determined empirically. The outputs of RSI are the signal contributions of each separable diffusion component.Purpose To understand the diffusion-weighted MRI signal of cancerous and healthy breast tissues in the context of RSI.Study Type Prospective.Populations 74 women, from two sites, with pathology-proven breast cancer.Field Strength/Sequence 3.0TAssessment The DW-MRI signal was described using a linear combination of a variable number of exponential components. The ADC for each component was estimated across all voxels from control and cancer regions of interest (ROIs), patients and sites. Once ADCs were determined, the signal contributions of each diffusion component were estimated using these fixed ADC values. Conventional ADC (mono-exponential) values were also estimated.Statistical Tests The relative fitting residual and relative Bayesian information criterion (BIC) were assessed. The signal contributions of each diffusion component were compared using analysis of variance (ANOVA) and post-hoc tests.Results Estimated ADCs for the bi-exponential model were D1,2 = 2.0 × 10−5 and D2,2 = 2.2 × 10−3 mm2/s, and D1,3=0, D2,3 = 1.4 × 10−3 and D3,3=10.2 × 10−3 mm2/s for tri-exponential model, which in practice is reduced to a bi-exponential model with an offset, or a three-component model. The relative fitting residuals of conventional ADC, bi-exponential and three-component models in control ROIs were 2.1%, 1.62%, and 1.03%, and 3.3%, 1.0%, and 0.3% for cancer ROIs. BIC was smaller for the three-component model, indicating an improved fitting of breast DW-MRI data compared to the bi-exponential model.Conclusion Breast DW-MRI signal was best described using a tri-exponential model. The signal contributions of the slower component in bi- or tri-exponential models were larger in tumor lesions. These data may be used as differential features between healthy and malignant breast tissues.Competing Interest StatementDr. Dale reports that he was a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. He receives funding through research grants from GE Healthcare to UCSD. Dr. Rakow-Penner is a consultant for Human Longevity, Inc. and receives funding through research grants from GE Healthcare. The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies.Funding StatementCalifornia Breast Cancer Research Program Early Career Award, GE Healthcare, NIH/NIBIB #K08EB026503, Fulbright Scholarship Program and the Research Council of Norway.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request. Please contact Dr. Dale and Dr. Rakow-Penner for further information. ER -